



## **Theratechnologies Comments on Current Market Activity**

**Montreal, Canada – June 20, 2008** –In the context of the current market activity and the recent positive clinical results, Theratechnologies (TSX:TH) confirms that its strategic review process is still active and ongoing and that it is entertaining discussions with a number of companies at this time. The Committee of Independent Directors of the Board is closely monitoring the process and regularly reporting to the Board of Directors. No decision has yet been made, and as previously stated on January 29, 2008, the Company will advise its shareholders of any material development in due course.

### **About Theratechnologies**

Theratechnologies (TSX: TH) is a Canadian biopharmaceutical company that discovers innovative drug candidates in order to develop them and bring them to market. The Company targets unmet medical needs in financially attractive specialty markets. Its most advanced program is tesamorelin, now in a confirmatory Phase 3 clinical trial for a serious metabolic disorder known as HIV-associated lipodystrophy. The Company also has other projects at earlier stages of development.

### **Contact:**

Andrea Gilpin  
Vice President, IR & Communications  
Theratechnologies Inc.  
514 336-7800 x 205  
[communications@theratech.com](mailto:communications@theratech.com)